Nkarta, Inc. (NKTX)

Market Cap	148.55M
Revenue (ttm)	n/a
Net Income (ttm)	-110.61M
Shares Out	70.57M
EPS (ttm)	-1.79
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	272,563
Open	2.290
Previous Close	2.150
Day's Range	2.075 - 2.210
52-Week Range	1.960 - 16.240
Beta	0.85
Analysts	Strong Buy
Price Target	15.20 (+622.09%)
Earnings Date	Mar 20, 2025

About NKTX

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company’s lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical tr...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 10, 2020
• Employees: 150
• Stock Exchange: NASDAQ
• Ticker Symbol: NKTX
• Website: https://www.nkartatx.com

Analyst Forecast

According to 5 analysts, the average rating for NKTX stock is "Strong Buy." The 12-month stock price forecast is $15.2, which is an increase of 622.09% from the latest price.

Price Target

$15.2

(622.09% upside)

Analyst Consensus: Strong Buy